0000000000082722
AUTHOR
Banumathy Gowrishankar
showing 2 related works from this author
Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma.
2016
e16109Background: Sunitinib is a 1st-line therapy for clear cell Renal Cell Carcinoma (ccRCC); however, 20-30% of tumors show primary resistant disease with progression as the best response. This s...
Novel chromosome copy number changes to predict clinical response to sunitinib in patients with advanced renal cell carcinoma
2015
4552 Background: Sunitinib is a 1st-line therapy for clear cell Renal Cell Carcinoma (ccRCC); however, 20-30% of tumors show primary resistant disease (PRD) with progression as the best response. T...